Utah’s Control Medical Technology Gets FDA Clearance for New Mechanical Thrombectomy Platform
May 8, 2020
Control Medical Technology announced on May 7 that the FDA cleared the company’s Control 7 – 11F Mechanical Thrombectomy platform to remove blood clots from peripheral vessels. The device provides clinicians with a more cost-effective tool to remove blood clots.
“This FDA clearance quadruples our product offering and improves our ability to help patients,” said Shawn Fojtik, President of Control Medical Technology in Park City, Utah.
“This new device will help save lives,” said Kelvyn Cullimore, president and CEO of BioUtah. “With Shawn’s leadership, I’m confident that Control Medical Technology will continue to deliver innovative technologies for use in peripheral, coronary, and neurovascular procedures.”
Blood clot removal (thrombectomy) is a common procedure. Coronary thrombectomy is associated with acute myocardial infarction (AMI), neurovascular thrombectomy is associated with acute ischemic stroke, and peripheral thrombectomy is associated with peripheral arterial disease (PAD), acute limb ischemia (ALI), critical limb ischemia (CLI), chronic total occlusion (CTO), deep vein thrombosis (DVT), pulmonary embolism (PE), and other peripheral vascular disease (PVD). Peripheral thrombectomy is associated with peripheral arterial disease (PAD), acute limb ischemia (ALI), critical limb ischemia (CLI), chronic total occlusion (CTO), deep vein thrombosis (DVT), pulmonary embolism (PE), and other peripheral vascular disease (PVD).
Recent News
- Webinar Recap: Immigration Compliance Under Pressure
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services